What Precedes Aid With Dying in Young Adults With Cancer? Edited by Gargi Mukherjee April 20, 2026 +++++

https://www.medscape.com/viewarticle/what-precedes-aid-dying-young-adults-cancer-2026a1000cbq In a retrospective cohort study of 34 adolescent and young adult patients with cancer who received medical assistance in dying (MAID) in Alberta, Canada, symptom burden increased sharply about 5 months before death, yet only half received specialist palliative care within 3 months of death. Patients experienced high symptom complexity, particularly tiredness, poor well-being, and pain, and 80% cited the loss of ability to engage in meaningful activities as the primary source of suffering. Vitamin C’s Potential Use in Cancer Is Getting a Second Look Alice McCarthy https://www.medscape.com/viewarticle/vitamin-cs-potential-use-cancer-getting-second-look-2026a1000ca3 April 20, 2026 When Garry Buettner, PhD, who has been studying the chemistry and biochemistry of vitamin C for at least four decades, was diagnosed with myelodysplastic syndromes (MDS), he applied his research to his own life — reviewing the data and designing a protocol for his treatment. Immunotherapy Combo Shows Promise for Hodgkin Lymphoma Edited by Gargi Mukherjee https://www.medscape.com/viewarticle/immunotherapy-combo-shows-promise-hodgkin-lymphoma-2026a1000c8x April 20, 2026 Brentuximab vedotin and nivolumab combined with doxorubicin and dacarbazine (AN+AD) was associated with a high complete response rate and encouraging short-term progression‑free survival (PFS) in patients with nonbulky early-stage classical Hodgkin lymphoma (cHL), according to a recent phase 2 study. Any‑grade treatment‑emergent adverse events occurred in almost all patients, and peripheral sensory neuropathy was common, but most cases were low-grade and resolved or improved, and no cases of febrile neutropenia were reported. Osimertinib Maintains Quality of Life in Patients With Stage III EGFR-Mutated NSCLC After Chemoradiotherapy Edited by Vineeta Teotia https://www.medscape.com/viewarticle/osimertinib-maintains-quality-life-patients-stage-iii-egfr-2026a1000byu Osimertinib maintained health-related quality of life (QOL) and functioning in patients with unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after definitive chemoradiotherapy, with no clinically meaningful deterioration in patient-reported outcome (PRO) scores. Is Vitamin D a Key to Better Breast Cancer Survival? Ernie Mundell https://www.medscape.com/viewarticle/vitamin-d-key-better-breast-cancer-survival-2026a1000c9y April 20, 2026 For women with breast cancer, vitamin D levels around the time of diagnosis might be related to long-term survival, a large prospective study showed.